Standard BioTools Inc. Total Contract Liability
Standard BioTools Inc. (LAB) had Total Contract Liability of $12.29 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2026-08-05
- 2026-06-30: Contract with Customer, Liability $12.29M.
- 2026-03-31: Contract with Customer, Liability $12.99M.
- 2025-12-31: Contract with Customer, Liability $42.45M.
- 2025-09-30: Contract with Customer, Liability $42.48M.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2026-06-30 | $12.29M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $12.99M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $42.45M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $42.48M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $42.95M 10-Q · filed 2025-08-15 | |
| 2025-03-31 | $45.31M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $42.95M 10-K · filed 2026-03-16 | $45.79M 10-K · filed 2025-03-11 |
| 2024-09-30 | $46.12M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $48.51M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $47.76M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $15.13M 10-K · filed 2026-03-16 | $15.10M 10-K · filed 2024-03-01 |
| 2023-09-30 | $14.70M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $15.50M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $15.50M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $14.61M 10-K · filed 2026-03-16 | $14.60M 10-K · filed 2023-03-14 |
| 2022-09-30 | $15.80M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $16.50M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $18.10M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $17.91M 10-K · filed 2025-03-11 | $17.90M 10-K · filed 2022-03-08 |
| 2021-09-30 | $18.90M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $20.50M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $21.40M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $21.50M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $21.10M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $22.20M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $21.10M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $20.00M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $19.40M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $18.30M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $18.40M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $17.80M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $17.20M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $15.50M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $16.00M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $15.20M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |